These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38089044)

  • 1. Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.
    Guan R; Li X; Ma G
    Front Pharmacol; 2023; 14():1326373. PubMed ID: 38089044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
    Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
    J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model.
    Rashid M; Sarfraz M; Arafat M; Hussain A; Abbas N; Sadiq MW; Rasool MF; Bukhari NI
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):56. PubMed ID: 32727574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil.
    Shen C; Liang D; Wang X; Shao W; Geng K; Wang X; Sun H; Xie H
    Front Pharmacol; 2022; 13():1013432. PubMed ID: 36278167
    [No Abstract]   [Full Text] [Related]  

  • 5. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
    Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights.
    Machado TR; Honorio T; Souza Domingos TF; Candido de Paula DDS; Cabral LM; Rodrigues CR; Abrahim-Vieira BA; Teles de Souza AM
    Br J Clin Pharmacol; 2023 Oct; 89(10):3175-3194. PubMed ID: 37293836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
    Maglalang PD; Sinha J; Zimmerman K; McCann S; Edginton A; Hornik CP; Hornik CD; Muller WJ; Al-Uzri A; Meyer M; Chen JY; Anand R; Perrin EM; Gonzalez D;
    Clin Pharmacokinet; 2024 Jun; 63(6):885-899. PubMed ID: 38814425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
    Huang W; Stader F; Chan P; Shemesh CS; Chen Y; Gill KL; Jones HM; Li L; Rossato G; Wu B; Jin JY; Chanu P
    Front Pharmacol; 2022; 13():974423. PubMed ID: 36225583
    [No Abstract]   [Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
    Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
    J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
    Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
    Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
    [No Abstract]   [Full Text] [Related]  

  • 14. Physiologically-Based Pharmacokinetic Modeling of Tenofovir Disoproxil Fumarate in Pregnant Women.
    Zhang X; Luo T; Yang H; Ma WY; He Q; Xu M; Yang Y
    Curr Drug Metab; 2023; 23(14):1115-1123. PubMed ID: 36718061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.
    Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.
    Hanke N; Kunz C; Thiemann M; Fricke H; Lehr T
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30939793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of
    Li X; Chen C; Ding N; Zhang T; Zheng P; Yang M
    Front Pharmacol; 2022; 13():1073535. PubMed ID: 36588682
    [No Abstract]   [Full Text] [Related]  

  • 20. A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations.
    Talha Zahid M; Zamir A; Majeed A; Imran I; Alsanea S; Ahmad T; Alqahtani F; Fawad Rasool M
    Saudi Pharm J; 2023 Aug; 31(8):101675. PubMed ID: 37576858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.